Marvel Biosciences Corp Stock Price, News & Analysis

Marvel Biosciences (OTC: MBCOF) announced it is accelerating the expiry of warrants issued in its non‑brokered private placement (5,000,000 units at $0.10 per unit) after the listed VWAP trigger occurred.

Each unit included one common share and one warrant exercisable at $0.15 until July 19, 2026, subject to acceleration if the TSXV VWAP ≥ $0.175 for five consecutive trading days. The Triggering Event occurred as of October 3, 2025 and the Company set November 5, 2025 as the Accelerated Expiry Date. To date 4,300,000 warrants have been exercised and 700,000 remain outstanding. Management highlighted continued progress toward Phase 1 trials.

Marvel Biosciences (OTCQB: MBCOF) has secured a significant patent in China for its lead therapeutic candidate MB-204, a novel fluorinated derivative of Istradefylline. The patent (ZL202180020893.4) covers the compound's composition of matter, which is designed to target autism spectrum disorder and related conditions.

MB-204 has demonstrated enhanced potency, longer duration, and improved tolerability in preclinical studies, showing efficacy in models of autism, Rett syndrome, and depression. The company is preparing to advance the drug candidate into Phase 1 clinical trials, addressing a significant market need with approximately 1 in 36 children diagnosed with autism.

Marvel Biosciences (TSXV: MRVL) has granted 142,987 deferred share units (DSUs) to two directors as compensation in lieu of cash directors' fees. The DSUs are valued at $0.16 per unit based on the Volume Weighted Average Price (VWAP) of Marvel's common shares on the TSX Venture Exchange as of July 31, 2025.

The DSUs will vest on July 31, 2026 and will be settled upon the directors' separation from service, with an expiration period of 365 days after their departure.

Marvel Biosciences (TSXV: MRVL) has successfully closed its non-brokered private placement offering, raising gross proceeds of $1,018,750 through the issuance of 8,150,000 units at $0.125 per unit. Each unit consists of one common share and one purchase warrant.

The warrants allow holders to purchase additional common shares at $0.175 per share within a two-year period. The company included an acceleration clause where the warrant expiry can be brought forward if the stock trades at $0.30 or higher for 10 consecutive trading days, with a 30-day notice period for warrant holders to exercise.

Marvel Biosciences (TSXV: MRVL) has closed the second tranche of its non-brokered private placement, issuing 150,000 Units at $0.125 per Unit for gross proceeds of $18,750. Each Unit consists of one Common Share and one Warrant. The company paid $1,312.50 in finder's fees and issued 10,500 finder's warrants, exercisable at $0.175 per share for two years. The total offering aims to raise up to $1.5 million through 12 million Units. The proceeds will fund drug formulation, toxicology studies, and working capital. The company also corrected its March 28 press release regarding finder's fees and announced the termination of a previously announced private placement from January 7, 2025.

Marvel Biosciences has announced significant results from its preclinical Rett syndrome study comparing MB-204 to Trofinetide. The study revealed that MB-204, administered at 10 mg/kg orally once daily, demonstrated superior and longer-lasting effects compared to Trofinetide (100 mg/kg injected).

Key findings show MB-204 maintained effectiveness for up to three weeks after treatment cessation, significantly outperforming Trofinetide in reversing social behavioral deficiencies. The drug showed remarkable results in multiple behavioral tests, including nose contacts, paw contacts, and following episodes (p<0.0001 vs control).

The research, conducted at the iBraiN Institute, will be presented at the International Rett Syndrome Foundation Scientific Meeting in Boston, June 2025. Scientists noted MB-204's potential as a novel treatment for both Rett syndrome and autism, highlighting its sustained effectiveness without reduction after chronic dosing.

Marvel Biosciences (TSXV: MRVL, OTCQB: MBCOF) has been selected to present at the International Rett Syndrome Foundation (IRSF) Scientific Meeting from June 9-11th, 2025. Dr. Mark Williams, Chief Science Officer, will present the company's latest preclinical studies of MB-204 in Rett Syndrome and Autism Spectrum Disorder (ASD).

The research was conducted in collaboration with Dr. Julie Le Merrer and Dr. Jérôme Becker from the iBraiN Institute in Tours, France, producing promising preclinical data. The company plans to publish full study results in a peer-reviewed journal and is preparing to submit an application for Orphan Drug Designation for MB-204 as a Rett syndrome treatment with the U.S. FDA.

Marvel Biosciences (TSXV: MRVL) (OTCQB: MBCOF) has been selected to present groundbreaking Alzheimer's disease research at the prestigious Alzheimer's Association International Conference in July 2025.

The presentation will showcase preclinical data from their acute Alzheimer's study, conducted with Professor Emmanuel Planel, focusing on their compound MB-204. The research demonstrated significant reduction in tau hyperphosphorylation in mice, suggesting potential as a disease-modifying therapy.

Additionally, Marvel is conducting a chronic Alzheimer's study using the 5xFAD model, backed by an Alberta Innovates grant. This ongoing research evaluates MB-204's effects on cognition, behavior, and disease pathology, with results expected in Q3 2025.

Marvel Biosciences (TSXV: MRVL) has closed the first tranche of a non-brokered private placement, raising $1,000,000 through the issuance of 8,000,000 units at $0.125 per unit. The total offering aims to raise up to $1.5 million through 12,000,000 units.

Each unit consists of one common share and one purchase warrant exercisable at $0.175 per share for two years. The warrant expiry can be accelerated if the stock trades at $0.30 or higher for 10 consecutive trading days.

The company paid $54,950 in finder's fees and issued 383,600 finder's warrants. Proceeds will fund drug formulation, toxicology studies, and working capital. The securities are subject to a four-month hold period.